Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Performance is a commercially available sports and oral rehydration drink manufactured by Shaklee Corp. It is formulated with a specific blend of electrolytes, including citrate (19.5 mmol/L), sodium (21 mmol/L), potassium (5.3 mmol/L), and calcium (0.8 mmol/L). In a clinical trial (NCT00381277) sponsored by the VA New York Harbor Healthcare System, the beverage was evaluated for its impact on urinary lithogenicity in healthy volunteers. The study demonstrated that Performance significantly increases urinary citrate excretion and urine pH, which are key factors in reducing the risk of urolithiasis (kidney stone formation). Unlike traditional pharmaceutical interventions, Performance is categorized as a dietary supplement or consumer beverage rather than a targeted therapeutic drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Performance (Department of Veterans Affairs New York Harbor Healthcare System).